Kolexia
Thepot Sylvain Hématologie
Thepot Sylvain
Hématologie
Hôpital Larrey Angers
Angers, France
189 Activités
144 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndromes myélodysplasiques Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Leucémie myélomonocytaire chronique Préleucémie Maladie du greffon contre l'hôte Anémie Tumeurs hématologiques

Collaborateurs

Voir plus
Fenaux Pierre
Fenaux Pierre
Hôpital Saint-Louis, Paris, France
Ades Lionel
Ades Lionel
Hôpital Saint-Louis, Paris, France
Itzykson Raphael
Itzykson Raphael
Hôpital Saint-Louis, Paris, France
Vey Norbert
Vey Norbert
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Celgene
5 collaboration(s)
Dernière en 2023
Astellas
4 collaboration(s)
Dernière en 2022
Novartis
3 collaboration(s)
Dernière en 2023
Therakos
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS): A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
Essai Clinique (BMS)   13 mars 2024
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Essai Clinique (Syros Pharmaceuticals)   11 mars 2024
A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes: A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
Essai Clinique (Keros Therapeutics, Inc.)   11 mars 2024
MO-TRANS: Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT
Essai Clinique (Priothera SAS)   01 mars 2024
Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS): A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Essai Clinique (Geron Corporation)   28 février 2024
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML: Tamibarotene in Combination With Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy
Essai Clinique (Syros Pharmaceuticals)   21 février 2024
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
Leukemia   17 février 2024
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Annals of hematology   26 janvier 2024
AVENHIR: Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)
Essai Clinique (Abbvie)   02 janvier 2024
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA: A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Essai Clinique (Celgene)   02 janvier 2024